Clinical Rheumatology

, Volume 38, Issue 2, pp 603–608 | Cite as

Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab

  • Rahaf Baker
  • Jean W. LiewEmail author
  • Paul D. Simonson
  • Lori A. Soma
  • Gordon Starkebaum
Case Based Review


Macrophage activation syndrome (MAS) is a rare and potentially fatal condition characterized by excessive activation and uncontrolled proliferation of T lymphocytes and macrophages, leading to overwhelming systemic inflammation and cytokine release. MAS has been reported with viral infections, autoimmune disorders, malignancies, and medications. We describe a case of a patient with axial spondyloarthritis (axSpA) treated with adalimumab, who presented with MAS.


Adalimumab Axial spondylitis Fever Hemophagocytic lymphohistiocytosis Macrophage activation syndrome 


Compliance with ethical standards




  1. 1.
    Ravelli A, Minoia F, Davi S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 75:481–489CrossRefGoogle Scholar
  2. 2.
    Schram AM, Berliner N (2015) How I treat hemophagocytic lymphohistocytosis in the adult patient. Blood 125:2908–2914CrossRefGoogle Scholar
  3. 3.
    Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, Requena-Caballero L, Jordan MB, Abdel-Wahab O, Allen CE, Charlotte F, Diamond EL, Egeler RM, Fischer A, Herrera JG, Henter JI, Janku F, Merad M, Picarsic J, Rodriguez-Galindo C, Rollins BJ, Tazi A, Vassallo R, Weiss LM, for the Histiocyte Society (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681CrossRefGoogle Scholar
  4. 4.
    Grom AA, Horne A, De Benedetti F (2016) Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12:259–268CrossRefGoogle Scholar
  5. 5.
    Schram AM, Campigotto F, Mullally A et al (2015) Marked hyperferritinemia does not predict for HLH in the adult population. Blood 10:602–607Google Scholar
  6. 6.
    Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 14:603–618CrossRefGoogle Scholar
  7. 7.
    Lou YJ, Jin J, Mai QY (2007) Ankylosing spondylitis presenting with macrophage activation syndrome. Clin Rheumatol 26(11):1929–1930CrossRefGoogle Scholar
  8. 8.
    Larroche C, Falgarone G, Dumont Fischer D, Dhote R (2010) Syndrome d’activation macrophagique sous biothérapies: deux cas. Rev Med Interne 31S:S404–S501. Google Scholar
  9. 9.
    Sterba G, Sterba Y, Stempel C, Blank J, Azor E, Gomez L (2010) Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. Isr Med Assoc J 12:443–445Google Scholar
  10. 10.
    Aikawa NE, Carvalho JF, Bonfa E et al (2009) Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis. Isr Med Assoc J 11:635–636Google Scholar
  11. 11.
    Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30:401–403Google Scholar
  12. 12.
    Sandhu C, Chesney A, Piliotis E, Buckstein R, Koren S (2007) Macrophage activation syndrome after etanercept treatment. J Rheumatol 34:241–242Google Scholar
  13. 13.
    Molto A, Mateo L, Lloveras N et al (2010) Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 77:271–273CrossRefGoogle Scholar
  14. 14.
    Soubani L, Dridi L, Abdelghani KB et al (2014) Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset still’s disease. Pan Afr Med J 17:94Google Scholar
  15. 15.
    Agarwal S, Moodley J, Goel GA et al (2011) A rare trigger for macrophage activation syndrome. Rheumatol Int 31:405–407CrossRefGoogle Scholar
  16. 16.
    Chauveau E, Terrier F, Casassus-Builble D et al (2005) Syndrome d’activation macrophagique apres traitement par infliximab pour maladie de crohn fistulisee. Presse Med 34:583–584CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Rahaf Baker
    • 1
  • Jean W. Liew
    • 2
    • 3
    Email author
  • Paul D. Simonson
    • 4
  • Lori A. Soma
    • 4
  • Gordon Starkebaum
    • 2
  1. 1.University of Washington School of MedicineSeattleUSA
  2. 2.Division of Rheumatology, Department of MedicineUniversity of Washington School of MedicineSeattleUSA
  3. 3.University of WashingtonSeattleUSA
  4. 4.Department of Laboratory Medicine, Division of HematopathologyUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations